Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma

Multiple myeloma (MM), one of the most common hematological neoplasms worldwide, originates from malignant plasma cells in the bone marrow. MM remains an incurable disease, although continued treatment advancements have markedly increased overall survival. Many patients with MM eventually experience